HELP
Cybin D/B/A Helus Pharma
Price Chart
Latest Quote
$5.08
+0.23 (+4.64%)
Current Price
| Previous Close | $4.85 |
| Open | $5.21 |
| Day High | $5.40 |
| Day Low | $4.97 |
| Volume | 3,110,587 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 49.89M |
| Cash Equivalents | $145K |
| Net Income | $-86.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $253.21M |
| EPS (TTM) | $-4.30 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $637.33M |
| Income | $-86.60M |
| Book/sh | $0.05 |
| Cash/sh | $0.00 |
| Employees | 50 |
Financial Ratios
| Quick Ratio | 12.36 |
| Current Ratio | 13.78 |
Returns & Margins
| ROA | -31.95% |
| ROE | -55.89% |
Ownership
| Insider Ownership | 3.72% |
| Institutional Ownership | 53.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.63 |
| P/B | 95.77 |
Analyst Data
| Recommendation | none |
| Target Price | $42.28 |
Technical Indicators
| SMA20 | $4.42 |
| SMA50 | $4.85 |
| SMA200 | $5.97 |
| RSI | 69.42 |
| ATR | 0.3367 |
| Shares Float | 101.54M |
| Short Ratio | 3.61 |
| Volatility | 0.70 |
| Rel Volume | 4.43 |
Performance History
| Week | +18.30% |
| Month | +8.44% |
| Quarter | +12.53% |
| 6 Months | -29.32% |
| YTD | -38.71% |
| Year | -31.51% |
| 3 Years | -51.79% |
| 5 Years | -92.02% |
| 10 Years | -89.85% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $5.07 | 3,110,587 |
| 2026-06-23 | $4.85 | 466,800 |
| 2026-06-22 | $4.85 | 746,300 |
| 2026-06-18 | $4.67 | 456,000 |
| 2026-06-17 | $4.58 | 728,600 |
| 2026-06-16 | $4.29 | 516,500 |
| 2026-06-15 | $4.25 | 612,500 |
| 2026-06-12 | $4.30 | 519,100 |
| 2026-06-11 | $4.05 | 543,500 |
| 2026-06-10 | $3.87 | 403,500 |
| 2026-06-09 | $3.92 | 816,300 |
| 2026-06-08 | $4.01 | 426,500 |
| 2026-06-05 | $4.15 | 829,900 |
| 2026-06-04 | $4.43 | 504,200 |
| 2026-06-03 | $4.30 | 517,000 |
| 2026-06-02 | $4.55 | 779,900 |
| 2026-06-01 | $4.69 | 680,100 |
| 2026-05-29 | $4.55 | 384,800 |
| 2026-05-28 | $4.49 | 324,900 |
| 2026-05-27 | $4.43 | 688,500 |
| 2026-05-26 | $4.43 | 637,100 |
About Cybin D/B/A Helus Pharma
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
đ° Latest News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-05-04T15:11:24ZDoes Robert Langerâs Arrival Reframe Confidence in Cybinâs (HELP) Clinical Strategy and Execution Risk?
Simply Wall St. âĸ 2026-04-25T12:05:33Z
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
MT Newswires âĸ 2026-04-24T14:19:44ZTrump Signed a Psychedelic Drugs Orderâand These 4 Stocks Surged
Barrons.com âĸ 2026-04-20T20:34:00Z
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
MT Newswires âĸ 2026-04-20T11:23:51ZCybin Insider Ups Holding By 105% During Year
Simply Wall St. âĸ 2026-04-19T12:17:41Z
Trump Trade: President to sign order on psychedelic used for PTSD
TipRanks âĸ 2026-04-17T21:56:03Z
Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?
Investor's Business Daily âĸ 2026-04-02T15:31:28Z
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data
Insider Monkey âĸ 2026-03-25T05:34:16Z
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data
Simply Wall St. âĸ 2026-03-09T05:05:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | $0 |
| Cost Of Revenue | - | - | - | $0 |
| Expenses | ||||
| Total Expenses | $101,371,720 | $55,828,909 | $36,483,253 | $45,207,848 |
| Other Income Expense | $15,382,056 | $97,019 | $2,425,466 | $-2,856,738 |
| Net Non Operating Interest Income Expense | $5,869,981 | $438,354 | $427,024 | $170,668 |
| Operating Expense | $101,371,720 | $55,828,909 | $36,483,253 | $45,207,848 |
| Selling And Marketing Expense | $2,327,031 | $1,986,867 | $623,894 | $1,038,170 |
| General And Administrative Expense | $60,159,339 | $22,370,200 | $17,807,521 | $31,715,885 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Net Interest Income | $5,869,981 | $438,354 | $427,024 | $170,668 |
| Interest Income | $5,869,981 | $438,354 | $427,024 | $170,668 |
| Normalized Income | $-95,501,738 | $-55,390,555 | $-36,056,230 | $-45,037,180 |
| Net Income From Continuing And Discontinued Operation | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Net Income Common Stockholders | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Net Income | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Net Income Including Noncontrolling Interests | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Net Income Continuous Operations | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Pretax Income | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Special Income Charges | $-19,829 | $0 | $-242,192 | $-2,617,378 |
| Interest Income Non Operating | $5,869,981 | $438,354 | $427,024 | $170,668 |
| Operating Income | $-101,371,720 | $-55,828,909 | $-36,483,253 | $-45,207,848 |
| Gross Profit | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-3.96 | $-4.93 | $-7.00 | $-10.76 |
| Basic EPS | $-3.96 | $-4.93 | $-7.00 | $-10.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-116,417,397 | $-55,625,666 | $-38,730,969 | $-33,827,386 |
| Total Unusual Items | $15,382,056 | $97,019 | $2,425,466 | $-2,856,738 |
| Total Unusual Items Excluding Goodwill | $15,382,056 | $97,019 | $2,425,466 | $-2,856,738 |
| Reconciled Depreciation | $336,378 | $300,262 | $177,749 | $118,972 |
| EBITDA (Bullshit earnings) | $-101,035,341 | $-55,528,647 | $-36,305,504 | $-36,115,596 |
| EBIT | $-101,371,720 | $-55,828,909 | $-36,483,253 | $-36,210,890 |
| Diluted Average Shares | $14,320,865 | $5,875,908 | $3,455,636 | $3,117,552 |
| Basic Average Shares | $14,320,865 | $5,875,908 | $3,455,636 | $3,117,552 |
| Diluted NI Availto Com Stockholders | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Other Special Charges | $19,829 | - | - | - |
| Gain On Sale Of Security | $15,401,884 | $97,019 | $2,667,658 | $-239,360 |
| Research And Development | $38,885,349 | $22,917,641 | $18,051,838 | $12,453,793 |
| Selling General And Administration | $62,486,370 | $32,911,268 | $18,431,415 | $32,754,055 |
| Other Gand A | $20,491,467 | $10,769,750 | $10,047,447 | $13,659,090 |
| Salaries And Wages | $39,667,872 | $15,674,528 | $7,760,074 | $18,056,796 |
| Restructuring And Mergern Acquisition | - | $0 | $242,192 | $2,617,378 |
| Write Off | - | - | - | $0 |
| Impairment Of Capital Assets | - | - | - | $0 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $102,467,959 | $147,997,314 | $12,727,144 | $36,243,893 |
| Total Assets | $183,144,260 | $213,882,169 | $38,167,978 | $59,530,489 |
| Total Non Current Assets | $65,608,670 | $59,122,586 | $21,749,169 | $18,205,510 |
| Goodwill And Other Intangible Assets | $65,508,819 | $58,735,219 | $21,430,494 | $17,686,425 |
| Other Intangible Assets | $29,047,519 | $25,115,078 | $3,873,663 | $1,475,108 |
| Current Assets | $117,535,590 | $154,759,584 | $16,418,809 | $41,324,978 |
| Other Current Assets | $2,060,052 | $1,541,676 | $1,252,744 | $949,649 |
| Prepaid Assets | $15,690,108 | $2,047,306 | $1,227,250 | $900,078 |
| Receivables | $4,167,552 | $3,169,747 | $2,159,904 | $1,488,563 |
| Accounts Receivable | $4,167,552 | $3,169,747 | $2,159,904 | $1,488,563 |
| Cash Cash Equivalents And Short Term Investments | $95,617,878 | $148,000,855 | $11,778,911 | $37,986,688 |
| Cash And Cash Equivalents | $95,617,878 | $148,000,855 | $11,778,911 | $37,986,688 |
| Cash Financial | $95,617,878 | $148,000,855 | $11,778,911 | $37,986,688 |
| Debt | ||||
| Total Debt | $0 | $206,076 | - | - |
| Current Debt And Capital Lease Obligation | - | $206,076 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,167,482 | $7,149,636 | $4,010,339 | $5,600,170 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $15,167,482 | $7,149,636 | $4,010,339 | $5,600,170 |
| Payables And Accrued Expenses | $15,167,482 | $5,138,810 | $4,010,339 | $5,600,170 |
| Payables | $15,167,482 | $5,138,810 | $4,010,339 | $5,600,170 |
| Accounts Payable | $15,167,482 | $6,943,559 | $4,010,339 | $3,726,365 |
| Other Payable | - | $206,076 | - | $1,873,805 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Other Non Current Liabilities | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $167,976,778 | $206,732,534 | $34,157,639 | $53,930,319 |
| Total Equity Gross Minority Interest | $167,976,778 | $206,732,534 | $34,157,639 | $53,930,319 |
| Stockholders Equity | $167,976,778 | $206,732,534 | $34,157,639 | $53,930,319 |
| Other Equity Interest | $53,127,259 | $45,900,434 | $27,020,750 | $24,931,663 |
| Gains Losses Not Affecting Retained Earnings | $-5,120,742 | $-1,618,157 | $-1,441,116 | $-259,188 |
| Other Equity Adjustments | $-5,120,742 | $-1,618,157 | $-1,441,116 | $-259,188 |
| Retained Earnings | $-240,328,597 | $-160,208,915 | $-104,915,378 | $-71,284,614 |
| Other | ||||
| Ordinary Shares Number | $15,303,948 | $14,164,970 | $3,650,019 | $3,087,738 |
| Share Issued | $15,303,948 | $14,164,970 | $3,650,019 | $3,087,738 |
| Tangible Book Value | $102,467,959 | $147,997,314 | $12,727,144 | $36,243,893 |
| Invested Capital | $167,976,778 | $206,732,534 | $34,157,639 | $53,930,319 |
| Working Capital | $102,368,108 | $147,609,948 | $12,408,470 | $35,724,808 |
| Capital Lease Obligations | $0 | $206,076 | - | - |
| Total Capitalization | $167,976,778 | $206,732,534 | $34,157,639 | $53,930,319 |
| Additional Paid In Capital | $31,452,448 | $8,320,941 | $1,488,563 | $371,787 |
| Capital Stock | $328,846,411 | $314,338,231 | $112,004,820 | $100,170,671 |
| Common Stock | $328,846,411 | $314,338,231 | $112,004,820 | $100,170,671 |
| Current Capital Lease Obligation | $0 | $206,076 | - | - |
| Goodwill | $36,461,300 | $33,620,141 | $17,556,831 | $16,211,317 |
| Net PPE | $99,851 | $387,366 | $318,674 | $347,709 |
| Accumulated Depreciation | $-599,816 | $-571,489 | $-320,799 | $-157,213 |
| Gross PPE | $699,667 | $958,856 | $639,473 | $504,922 |
| Other Properties | $485,801 | $770,484 | $470,222 | $336,378 |
| Machinery Furniture Equipment | $213,866 | $188,372 | $169,251 | $168,543 |
| Treasury Shares Number | - | $0 | - | - |
| Investments And Advances | - | - | $0 | $171,376 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-73,129,384 | $-49,301,043 | $-35,932,301 | $-32,382,269 |
| Operating Activities | ||||
| Operating Cash Flow | $-71,737,132 | $-48,798,246 | $-33,588,982 | $-32,014,023 |
| Cash Flow From Continuing Operating Activities | $-71,737,132 | $-48,798,246 | $-33,588,982 | $-32,014,023 |
| Operating Gains Losses | $-15,401,884 | $-97,019 | $-2,850,365 | $218,823 |
| Investing Activities | ||||
| Capital Expenditure | $-1,392,253 | $-502,797 | $-2,343,319 | $-368,246 |
| Investing Cash Flow | $-1,392,253 | $4,901,919 | $-2,343,319 | $-545,287 |
| Cash Flow From Continuing Investing Activities | $-1,392,253 | $4,901,919 | $-2,343,319 | $-545,287 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $14,508,180 | $180,298,852 | $9,349,197 | $22,312,160 |
| Financing Cash Flow | $14,302,812 | $180,232,993 | $9,605,552 | $25,336,025 |
| Cash Flow From Continuing Financing Activities | $14,302,812 | $180,232,993 | $9,605,552 | $25,336,025 |
| Net Common Stock Issuance | $14,508,180 | $180,298,852 | $9,349,197 | $22,312,160 |
| Common Stock Issuance | $14,508,180 | $180,298,852 | $9,349,197 | $22,312,160 |
| Other | ||||
| Repayment Of Debt | $-205,368 | $-105,517 | $0 | - |
| End Cash Position | $95,617,878 | $148,000,855 | $11,778,911 | $37,986,688 |
| Beginning Cash Position | $148,000,855 | $11,778,911 | $37,986,688 | $45,340,983 |
| Effect Of Exchange Rate Changes | $6,443,595 | $-114,723 | $118,972 | $-131,011 |
| Changes In Cash | $-58,826,573 | $136,336,667 | $-26,326,748 | $-7,223,285 |
| Proceeds From Stock Option Exercised | $0 | $39,657 | $256,356 | $3,023,865 |
| Net Issuance Payments Of Debt | $-205,368 | $-105,517 | $0 | - |
| Net Long Term Debt Issuance | $-205,368 | $-105,517 | $0 | - |
| Long Term Debt Payments | $-205,368 | $-105,517 | $0 | - |
| Net Business Purchase And Sale | $0 | $5,404,717 | $0 | $0 |
| Sale Of Business | $0 | $5,404,717 | $0 | - |
| Net PPE Purchase And Sale | $-1,392,253 | $-372,112 | $-100,559 | $-74,357 |
| Purchase Of PPE | $-1,392,253 | $-372,112 | $-100,559 | $-74,357 |
| Change In Working Capital | $-6,935,062 | $-3,559,946 | $-1,017,633 | $150,839 |
| Change In Other Current Assets | $-518,377 | $-288,931 | $-303,095 | $-949,649 |
| Change In Payables And Accrued Expense | $8,223,922 | $-1,801,572 | $283,974 | $1,748,460 |
| Change In Prepaid Assets | $-13,642,802 | $-698,251 | $-327,172 | $-100,559 |
| Change In Receivables | $-997,805 | $-771,192 | $-671,341 | $-547,412 |
| Changes In Account Receivables | $-997,805 | $-771,192 | $-671,341 | $-547,412 |
| Other Non Cash Items | $24,786 | $5,665 | $229,446 | $2,602,507 |
| Stock Based Compensation | $30,358,333 | $9,833,582 | $3,318,462 | $12,768,218 |
| Asset Impairment Charge | $0 | $12,747 | $0 | $0 |
| Depreciation Amortization Depletion | $336,378 | $300,262 | $177,749 | $118,972 |
| Depreciation And Amortization | $336,378 | $300,262 | $177,749 | $118,972 |
| Amortization Cash Flow | $46,031 | $43,198 | $26,202 | $0 |
| Amortization Of Intangibles | $46,031 | $43,198 | $26,202 | $0 |
| Depreciation | $290,348 | $257,064 | $151,547 | $118,972 |
| Net Foreign Currency Exchange Gain Loss | $-15,401,884 | $-97,019 | $-2,850,365 | $218,823 |
| Net Income From Continuing Operations | $-80,119,683 | $-55,293,536 | $-33,630,764 | $-47,893,919 |
| Net Intangibles Purchase And Sale | - | $-487,926 | $-2,242,759 | $-293,889 |
| Purchase Of Intangibles | - | $-487,926 | $-2,242,759 | $-293,889 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $184,123 | $20,537 |
| Net Investment Purchase And Sale | - | - | $0 | $-177,041 |
| Purchase Of Investment | - | - | $0 | $-177,041 |
| Purchase Of Business | - | - | - | $0 |
| Change In Inventory | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-18